FDA Accepts Orexo’s Resubmitted IZIPRY NDA; PDUFA Date Set for March 29, 2027
The FDA accepted Orexo’s resubmitted NDA for IZIPRY, a naloxone nasal powder, and set a PDUFA target action date of March 29, 2027.
Related stories
Uganda warns boarding schools of sanctions over unlawful operations
Uganda’s Ministry of Education and Sports says it will act against boarding schools operating unlawfully, citing learner safety.
M impact | REGULATION | Oct 30, 2026, 09:06 AM UTC
Trump’s Tariffs Have Not Reduced the U.S. Trade Deficit, IW Says
The IW says Trump’s tariffs have not reduced the U.S. trade deficit.
M impact | REGULATION | Oct 30, 2026, 07:52 AM UTC
US Sanctions Rwanda Military Amid Stalled Congo Peace Talks
The US imposed sanctions on Rwanda’s military as an EU envoy and Uganda’s Museveni criticized stalled Congo peace talks.
M impact | REGULATION | Oct 30, 2026, 07:38 AM UTC
IW Report Says Trump's Tariffs Failed to Cut US Trade Deficit
A report by the German Economic Institute (IW) says U.S. tariffs did not reduce the trade deficit.
M impact | REGULATION | Oct 30, 2026, 07:01 AM UTC
US Offers Audi a Tariff on Imports, Insider Says
A source identified as an insider says the United States offered Audi a tariff on imports.
M impact | REGULATION | Oct 30, 2026, 05:25 AM UTC
Beijing Urban Construction Design Public Float Falls Below 25% Minimum
The company’s public float was 23.70% as of Oct. 30, below the required 25% minimum.
L impact | REGULATION | Oct 30, 2026, 04:03 AM UTC